These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2500273

  • 1. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
    Garbett ND, Currie DC, Cole PJ.
    Clin Exp Immunol; 1989 Apr; 76(1):1-7. PubMed ID: 2500273
    [Abstract] [Full Text] [Related]

  • 2. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ.
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [Abstract] [Full Text] [Related]

  • 3. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D.
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [Abstract] [Full Text] [Related]

  • 4. High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis.
    Hansbrough JF, Miller LM, Field TO, Gadd MA.
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S49-56. PubMed ID: 3041358
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-Hüber J, Zenker O, Grimbacher B.
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [Abstract] [Full Text] [Related]

  • 6. [Anaphylactic shock reaction following intravenous administration of 7S immunoglobulin in patients with hypogammaglobulinemia, especially in children with acute lymphoblastic leukemia (ALL)].
    Manzke H, Seifert J.
    Klin Padiatr; 1987 Oct; 199(4):274-8. PubMed ID: 3116320
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of treatment of children with hypogammaglobulinemia: comparison of fresh plasma and intravenous immunoglobulin preparation.
    Bernatowska E, Weremowicz R, Janowicz W, Madaliński K.
    Arch Immunol Ther Exp (Warsz); 1986 Oct; 34(4):377-84. PubMed ID: 3099724
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Immunoglobulin replacement therapy contribution in agammaglobulinemia: 10 case reports].
    Ksouri H, Mellouli F, Barbouch R, Ben Hassen A, Béjaoui M.
    Arch Pediatr; 2006 Jul; 13(7):1034-9. PubMed ID: 16713207
    [Abstract] [Full Text] [Related]

  • 10. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia.
    Roifman CM, Gelfand EW.
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S92-6. PubMed ID: 3399285
    [Abstract] [Full Text] [Related]

  • 11. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J, Lokaj J, Stikarovská D, Mayer J, Thon V, Eibl MM.
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [Abstract] [Full Text] [Related]

  • 12. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.
    Arthritis Res Ther; 2006 Nov; 8(4):R129. PubMed ID: 16859536
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of primary immunodeficiencies with intravenous gamma globulin].
    García Rodríguez C, López Trascasa M, Ferreira Cerdán A, Fontán Casariego G.
    An Esp Pediatr; 1987 Dec; 27(6):411-5. PubMed ID: 2451892
    [Abstract] [Full Text] [Related]

  • 18. A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin.
    Mondorf AW, Stephan W, Uthemann H, Schuppan D, Lissner R.
    Arzneimittelforschung; 1981 Dec; 31(11):1928-30. PubMed ID: 6797445
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB, Hanna K, IGIV-C in ITP Study Group.
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.